Alkermes plc. Lessee, Operating Lease, Liability, to be Paid, Year Five
Alkermes plc. (ALKS) had Lessee, Operating Lease, Liability, to be Paid, Year Five of $9.35 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive · last filed 2026-02-25
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year Five $9.35M.
- 2023-12-31: Lessee, Operating Lease, Liability, to be Paid, Year Five $9.57M.
- 2022-12-31: Lessee, Operating Lease, Liability, to be Paid, Year Five $9.51M.
- 2021-12-31: Lessee, Operating Lease, Liability, to be Paid, Year Five $13.78M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year Five |
|---|---|
| 2025-12-31 | $9.35M 10-K · filed 2026-02-25 |
| 2023-12-31 | $9.57M 10-K · filed 2024-02-21 |
| 2022-12-31 | $9.51M 10-K · filed 2023-02-16 |
| 2021-12-31 | $13.78M 10-Q · filed 2022-11-02 |
| 2020-12-31 | $17.81M 10-Q · filed 2021-10-27 |
| 2020-06-30 | $11.04M 10-Q · filed 2020-07-29 |
| 2020-03-31 | $10.90M 10-Q · filed 2020-04-29 |
| 2019-12-31 | $520.00K 10-K · filed 2021-02-11 |
| 2019-09-30 | $509.00K 10-Q · filed 2019-10-23 |
| 2019-06-30 | $509.00K 10-Q · filed 2019-07-25 |
| 2019-03-31 | $509.00K 10-Q · filed 2019-04-25 |
| 2018-12-31 | $2.39M 10-Q · filed 2019-07-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |